Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Microvascular Angina Clear all
Completed Not applicable Interventional

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

NCT02531334
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
TA-65
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
32 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Flavonoids on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome

NCT02728570
View directory record Official record
Conditions
Metabolic Syndrome X, Inflammation
Interventions
High Dietary Flavonoids, Low Dietary Flavonoids
Other
Lead sponsor
Utah State University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

NCT00909363
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions
Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Months to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Not yet recruiting Not applicable Interventional

Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA

NCT06948201
View directory record Official record
Conditions
Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease
Interventions
70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice), Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 21, 2026, 1:25 PM EDT
Suspended Phase 3 Interventional

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

NCT00243984
View directory record Official record
Conditions
Metabolic Syndrome X, Diabetes Mellitus, Type 2
Interventions
topiramate
Drug
Lead sponsor
Northeastern Ohio Universities College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Akron, Ohio • Canton, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Soy Nut Study on Markers of Health

NCT01173380
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Soy nuts, Matched food
Other
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inflammation and the Metabolic Syndrome in Humans

NCT00954824
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Endotoxin (LPS)
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jul 21, 2026, 1:25 PM EDT
Not listed No phase listed Observational

Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease

NCT04732091
View directory record Official record
Conditions
Acute Myocardial Infarction, Unstable Angina
Interventions
Therapeutic ultrasound with 20 usec
Procedure
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
30 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Not yet recruiting No phase listed Observational

Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study

NCT07676097
View directory record Official record
Conditions
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Interventions
Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
Procedure
Lead sponsor
AngioInsight
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individual Metabolism and Physiology Signature Study

NCT02298725
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome X, Obesity
Interventions
DGA Diet Plan, NHANES Diet Plan
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Davis, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults

NCT00318734
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome X, Hypertension, Inflammation, Atherosclerosis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 32 Years
Enrollment
4,362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jul 21, 2026, 1:25 PM EDT
Recruiting Phase 2 Interventional

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

NCT07523581
View directory record Official record
Conditions
Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Interventions
Exaluren
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

NCT02542176
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Freeze-dried Whole Grape Powder, Grape Powder Placebo
Other
Lead sponsor
University of Connecticut
Other
Eligibility
30 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 3 Interventional

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176
View directory record Official record
Conditions
Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 4 Interventional

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions
Aripiprazole
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jul 21, 2026, 1:25 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Omega-3 Fatty Acids on Metabolic Syndrome

NCT00350194
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Omega-3 fatty acids
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Jul 21, 2026, 1:25 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

NCT06424834
View directory record Official record
Conditions
Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions
Amlodipine, Nebivolol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Chromium Picolinate for the Treatment of Metabolic Syndrome

NCT00128154
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions
Chromium picolinate
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 21, 2026, 1:25 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress

NCT00177892
View directory record Official record
Conditions
Obstructive Sleep Apnea, Metabolic Syndrome X
Interventions
sleep disruption, sleep with and without positive pressure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2008 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

NCT01145066
View directory record Official record
Conditions
Diabetes, Metabolic Syndrome x
Interventions
borage/echium oil combination, fish oil, corn oil
Drug · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease

NCT02301663
View directory record Official record
Conditions
Microvascular Coronary Dysfunction
Interventions
Handgrip, Altitude simulation, Leg exercise
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 21, 2026, 1:25 PM EDT